UNITUXIN (dinutuximab) injection

UNITUXIN (dinutuximab) injection

UNITUXIN

dinutuximab

17.5 mg/5 mL (3.5 mg/mL) in a single-use via

United Therapeutics Corp.

Medical Use

Unituxin, also known as Ch14.18 or dinutuximab, is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis-retinoic acid to treat children with high-risk neuroblastoma. This drug is administered to patients whose condition has improved following other anticancer treatments. Unituxin targets GD2, a substance present on certain cancer cells, potentially blocking it and aiding the immune system in destroying these cells.